Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC By Ogkologos - July 14, 2025 436 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the IMforte study Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR Sen. Amy Klobuchar Announces Breast Cancer Diagnosis, Urges Women Not to... September 10, 2021 A Combination of Nivolumab Plus Ipilimumab Prolongs PFS versus Nivolumab Alone... February 5, 2025 Exercising While Living With Peripheral Neuropathy: What People Diagnosed With Cancer... May 2, 2023 EMA Recommends Granting a Conditional Marketing Authorisation for Epcoritamab August 17, 2023 Load more HOT NEWS ΚΑΡΚΙΝΟΣ ΤΡΑΧΗΛΟΥ ΜΗΤΡΑΣ Woman, 88, Had Been Waving from Her Window for Over a... Whole- and Partial-Breast Radiation Effective at Preventing Breast Cancer from Returning ESMO Welcomes EU Proposals for MFF & FP10 and Calls for...
